Loading
Latest filing published 27 Jan 2023 for Enveric Biosciences, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Jillian Marie Hagel, listed as senior executive, appears in our data through filings on Enveric Biosciences, Inc. shares, published by SEC (Form 4). Between 16 September 2021 and 25 January 2023, the trades on record add up to 5 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 27 January 2023, reports a share grant in Enveric Biosciences, Inc. Filings reach the SEC (Form 4) feed a median of 32 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations